U.S. Genotyping Market to Surge USD 26.53 Billion by 2034 at 13.72% CAGR

The U.S. genotyping market size is calculated at USD 8.34 billion in 2025 and is expected to reach around USD 26.53 billion by 2034, growing at a CAGR of 13.72% for the forecasted period.

Ottawa, Sept. 15, 2025 (GLOBE NEWSWIRE) -- The U.S. genotyping market size was valued at USD 7.33 billion in 2024 and is predicted to hit around USD 26.53 billion by 2034, rising at a 13.72% CAGR, a study published by Towards Healthcare a sister firm of Precedence Research.

The U.S. genotyping market is driven by its expanding healthcare applications, increasing research and development, and growing incidences of chronic diseases.

The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ https://www.towardshealthcare.com/download-sample/5160

Key Takeaways

By product, the reagents & kits segment held the major revenue share of 62% in the U.S. genotyping market in 2023.
By product, the services segment is expected to grow significantly at a CAGR of 13.62% during the forecast period.
By technology, the sequencing segment held a 23% share in the market in 2023.
By technology, the PCR segment is expected to grow significantly during the forecast period.
By application, the diagnostics and personalized medicine segment held a 35% share in the market in 2023
By application, the pharmacogenomics segment is expected to be the fastest growing with a CAGR of 14.52% during the forecast period.
By end-use, the diagnostics and research laboratories segment held a 37% share in the market in 2023.

Market Overview & Potential

The U.S Genotyping Market encompasses the identification of the variation in the genome by analyzing the DNA of the respective individual. These DNA sequences can be compared with the reference sequences with the use of appropriate bioassays. Therefore, genotyping is used for the early detection of genetic diseases and promotes the development of medications along with personalized treatments. Technologies such as the PCR technique, mass spectrometry, sequencing, capillary electrophoresis, etc., are used for genotyping. Moreover, the market is driven by rising genetic diseases, increasing use of personalized therapies, technological advancements, and growing R&D.

What are the Major Growth Drivers U.S. Genotyping Market?

The growing demand for personalized treatment approaches is increasing the use of genotyping in the U.S. These are being used to identify the genetic profile of the patient and help in the development of medications suitable for them. They are also being used to identify the targets along with the drug response. Furthermore, the growing incidence of genetic diseases and cancer are increasing their demand. The growing rates of chronic diseases, expanding pharmacogenomics, increasing genetic testing, etc., are some of the other market drivers.

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

What are the Key Drifts in the U.S. Genotyping Market?

The market has been expanding due to the growing acquisitions, collaborations, and funding to launch and enhance the use of various genotyping technologies.

In February 2025, the completion of the Deerfield Management Company, L.P. acquisition by Singular Genomics Systems, Inc., which is a company focusing on utilizing novel next-generation sequencing (NGS) and spatial multiomics technologies to support clinicians and researchers, was announced.
In February 2025, the acquisition of Officinae Bio’s DNA and RNA business by Maravai LifeSciences was announced to be completed. Thus, the transition from mRNA design to clinical development and production will be enhanced by merging the AI-enabled mRNA sequence-optimization platform of Officinae Bio with the manufacturing capabilities of Maravai and its subsidiary that is TriLink BioTechnologies.
In February 2025, to improve the clinical sample preparation and microbiology research of anaerobic organisms, Anaerobe Systems, Inc., was successfully acquired by Biolog, Inc. Moreover, J.P. Morgan Life Sciences Private Capital funded this acquisition.
In July 2024, the U.S. DNA sequencing firm Element Biosciences launched a Series D funding round of $277 million, where Samsung Electronics was announced to have participated as a strategic investor.

What is the Significant Challenge in the U.S. Genotyping Market?

Data privacy acts as a major limitation in the market, as it may lead to genetic data misuse. At the same time, the growing cybercrime can cause the identity theft of patients, which may decrease their use. Moreover, high cost, limited reimbursement policies, lack of skilled personnel, complex data interpretation, and regulatory hurdles can also restrain the market growth.

Regional Analysis

Why is the U.S. Significantly Growing in the U.S. Genotyping Market in 2023?

The U.S. is expected to grow significantly in the genotyping market during the forecast period. There is a rise in research and development focusing on various genetic diseases, which is increasing the use of genotyping for biomarker or target identification and drug discovery. The growing demand for personalized medicines is also increasing their use. Moreover, the growing R&D investments are increasing the adoption of advanced genotyping technologies. The growing clinical trials are also increasing their demand. Thus, this is promoting the market growth.

For instance,

In August 2025, a premium sequencing service, that is Whole Plasmid Sequencing – Express (WPS-Express), was launched and made available in certain U.S. locations, including San Diego, Houston, Boston, and San Francisco, by Quintara Biosciences.

Become a valued research partner with us - https://www.towardshealthcare.com/schedule-meeting

Segmental Insights

By product analysis

Why Did the Reagents & Kits Segment Dominate in the U.S. Genotyping Market in 2024?

By product, the reagents & kits segment held the largest share of 62% in the market in 2023, due to their continuous demand. These were crucial during genotyping, which increased their repeated use. At the same time growing development of ready-to-use kits also increased their use.

By product, the services segment is expected to show significant growth at a CAGR of 13.62% during the predicted time. There is a rise in the use of services due to growing research and development. They also offer customized genotyping solutions, which is increasing their acceptance rates. Moreover, the growing outsourcing is also increasing its use.

By technology analysis

Which Technology Type Segment Held the Dominating Share of the U.S. Genotyping Market in 2024?

By technology, the sequencing segment held the dominating share of 23% in the market in 2023, driven by its accuracy. This, in turn, increased their use in the rare disease diagnosis. Moreover, it was also used in pharmacogenomics. Furthermore, the growing cancer research has also increased its use.

By technology, the PCR segment is expected to show lucrative growth during the upcoming years. The use of PCR is increasing as it provides high sensitivity and specificity. This, in turn, is increasing its use in the infectious diseases and genetic disorders detection. Moreover, they are affordable and easily accessible.

By application analysis

What Made Diagnostics and Personalized Medicine the Dominant Segment in the U.S. Genotyping Market in 2024?

By application, the diagnostics and personalized medicine segment led the market with a 35% share in 2023, as genotyping was used in the development of personalized therapies. Its accuracy increased its use in the detection of various chronic diseases. This contributed to their increased adoption rates. Thus, this enhanced the market growth.

By application, the pharmacogenomics segment is expected to show the highest growth with a CAGR of 14.52% during the predicted time. The genotyping is being used to determine the drug responses and their side effects. They are also being used to improve the drug safety profile. Furthermore, their use in R&D as well as clinical trials is also increasing.

By end-user analysis

How the Diagnostics and Research Laboratories Segment Dominated the U.S. Genotyping Market in 2024?

By end-use, the diagnostics and research laboratories segment dominated the market with a 37% share, as genotyping is being used for diagnostic purposes. It is also being used for developing personalized treatment approaches. Moreover, their use in biomarker discovery is also increasing. Additionally, the growing collaboration is also increasing its use.

Get the latest insights on life science industry segmentation with our Annual Membership: https://www.towardshealthcare.com/get-an-annual-membership

Recent Developments in the U.S. Genotyping Market

In July 2025, four new Droplet Digital™ PCR (ddPCR™) platforms were launched by Bio-Rad Laboratories, Inc., which was developed by combining the QX Continuum™ ddPCR system of Bio-Rad and the QX700™ series of ddPCR platforms of Stilla Technologies.
In June 2025, to push the boundaries of scientific discovery, the Thermo Scientific™ Orbitrap™ Excedion™ Pro mass spectrometer (MS) and the Thermo Scientific™ Orbitrap™ Astral™ Zoom mass spectrometer (MS) were launched by Thermo Fisher Scientific Inc.
In April 2025, around 3 trillion DNA sequencing reads will be provided by Ultima Genomics for free of charge to researchers across the U.S. and Canada as per its newly launched "Count on Us" initiative.

U.S. Genotyping Market Key Players

Eurofins Scientific Inc.
Bio-Rad Laboratories Inc.
Agilent Technologies
GE Healthcare Inc.
Illumina Inc.
Danaher Corporation
QIAGEN
Fluidigm Corporation
F. Hoffmann-La Roche Ltd.
Thermo Fisher Scientific Inc.

Browse More Insights of Towards Healthcare:

The global gene editing therapeutics market is advancing rapidly, poised to generate hundreds of millions in revenue between 2025 and 2034.

In ophthalmology, the age-related macular degeneration (AMD) drugs market reached US$ 10.57 billion in 2024 and is projected to climb to US$ 11.69 billion in 2025, eventually hitting US$ 29.04 billion by 2034, reflecting a strong CAGR of 10.66% during the forecast period.

The gene transfer technologies market also demonstrates robust growth, valued at US$ 3.98 billion in 2024 and expected to grow to US$ 4.36 billion in 2025, with projections reaching US$ 9.97 billion by 2034, supported by a CAGR of 9.62%.

In the preclinical research space, the global mice model market expanded to US$ 1.73 billion in 2025 from US$ 1.57 billion in 2024, with forecasts indicating it will reach US$ 4.1 billion by 2034, growing at 10.04% CAGR.

Similarly, the synthetic tissue engineering market is set to soar from US$ 1.51 billion in 2024 to US$ 1.72 billion in 2025, and is expected to hit US$ 5.61 billion by 2034, registering an impressive CAGR of 14.14%.

The single nucleotide polymorphism (SNP) genotyping market is witnessing substantial expansion, with market size increasing from US$ 6.48 billion in 2024 to US$ 7.24 billion in 2025, and projected to reach US$ 19.48 billion by 2034, growing at 11.7% CAGR.

The cell and gene therapy thawing equipment market recorded US$ 0.96 billion in 2024, is set to reach US$ 1.1 billion in 2025, and is projected to climb to nearly US$ 3.56 billion by 2034, reflecting a CAGR of 14.24%.

In the services sector, the gene overexpression cell line construction market grew from US$ 788.63 million in 2024 to US$ 848.01 million in 2025, with expectations to reach US$ 1.63 billion by 2034, expanding at a CAGR of 7.53%.

The gene therapy cell culture media market is also on a strong growth path, starting at US$ 193.45 billion in 2024, rising to US$ 214.42 billion in 2025, and expected to surpass US$ 541.42 billion by 2034, growing steadily at a CAGR of 10.84%.

Finally, the gene knockout cell line construction market continues its upward trajectory, with revenue expected to reach hundreds of millions between 2025 and 2034.

Segments Covered in The Report

By Product

Instruments
Reagents & Kits
Software and Services

By Technology

PCR
Capillary Electrophoresis
Microarrays
Sequencing
Mass Spectrometry
Others

By Application

Pharmacogenomics
Diagnostics and Personalized Medicine
Agricultural Biotechnology
Animal Genetics
Others

By End-use

Pharmaceutical and Biopharmaceutical Companies
Diagnostics and Research Laboratories
Academic Institutes
Others

Immediate Delivery Available | Buy This Premium Research @ https://www.towardshealthcare.com/price/5160

Access our exclusive, data-rich dashboard dedicated to the healthcare market - built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.

Access the Dashboard: https://www.towardshealthcare.com/access-dashboard

About Us

Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth.

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

Europe Region: +44 778 256 0738

North America Region: +1 8044 4193 44

APAC Region: +91 9356 9282 04

Web: https://www.towardshealthcare.com

Our Trusted Data Partners

Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | Pinterest

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.